LH vs MEDP: Laboratory Corporation of America Holdings and Medpace compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Laboratory Corporation of America Holdings is the larger company, worth $25.9B, about 1.5 times Medpace.
- Medpace grew revenue faster over the last year (+17.2% vs +5.8%).
- Medpace keeps more of each dollar of revenue as operating profit (21.0% vs 10.4%).
- On earnings, Laboratory Corporation of America Holdings is the cheaper stock (28.0x vs 38.2x).
- Medpace's price assumes faster free cash flow growth: about 8% a year, against 6% for Laboratory Corporation of America Holdings (reverse DCF).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | LH | MEDP |
|---|---|---|
| Market cap | $25.9B | $17.3B |
| Share price | $312.15 | $612.05 |
| Revenue (last fiscal year) | $14.0B | $2.5B |
| Free cash flow (last fiscal year) | $1.2B | $682M |
| Revenue growth, last year | +5.8% | +17.2% |
| Revenue growth per year, last 5 fiscal years | +1.5% | +22.0% |
| Operating margin | 10.4% | 21.0% |
| Net margin | 7.0% | 17.7% |
| Return on equity | 11.7% | 113.3% |
| P/E (trailing) | 28.0x | 38.2x |
| Price / free cash flow | 21.5x | 25.4x |
| EV / EBITDA | 13.2x | 26.8x |
| FCF growth the price implies | 5.9% | 8.1% |
| Dividend yield | 0.92% | — |
| Debt / equity | 1.15x | 3.74x |
| Fundamental grade | C | C |
| Superinvestors holding it | 7 | 5 |
| Insider purchases, last 12 months | 10 | 4 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Laboratory Corporation of America Holdings
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $13.1B | $2.7B | 23.2% |
| 2022 | $11.9B | $1.5B | 12.1% |
| 2023 | $12.2B | $874M | 6.0% |
| 2024 | $13.0B | $1.1B | 8.4% |
| 2025 | $14.0B | $1.2B | 9.9% |
Medpace
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $1.1B | $235M | 17.4% |
| 2022 | $1.5B | $351M | 19.1% |
| 2023 | $1.9B | $397M | 17.9% |
| 2024 | $2.1B | $572M | 21.2% |
| 2025 | $2.5B | $682M | 21.1% |
Where the revenue comes from
Laboratory Corporation of America Holdings · by segments, 2025
Diagnostics$10.9B78%
Biopharma Laboratory Services$3.1B22%
Medpace · by products, 2025
Oncology$748M30%
Other$745M29%
Metabolic$409M16%
AVAI$255M10%
Central Nervous System$239M9%
Cardiology$135M5%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open LH in InvestinglyQuestions
Which is bigger, Laboratory Corporation of America Holdings or Medpace?
Laboratory Corporation of America Holdings (LH), at $25.9B against $17.3B.
Is LH or MEDP cheaper?
By trailing P/E, Laboratory Corporation of America Holdings (28.0x) is cheaper than Medpace (38.2x). A lower multiple can also mean the market expects less growth.
Which grows faster, LH or MEDP?
Medpace: revenue grew +17.2% over the last year, against +5.8%.
More comparisons
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.